Johnson & Johnson to Acquire Tibotec- Virco to Expand Portfolio of Treatments For Infectious Diseases and Add to R&D Capability
- Johnson & Johnson expects to incur one-time charge of approximately $145 million in the second quarter
26-Mar-2003 -
Johnson & Johnson today announced it has signed a definitive agreement to acquire all of the assets of Tibotec- Virco NV, a privately-held biopharmaceutical company focused on developing anti-viral treatments, with several promising compounds in development for the treatment of infectious ...
analytical services
Belgium
drug resistance
+6